The Latest Medical News

A Summary of The Latest Medical News: Eloralintide, an experimental once-weekly **weight loss injection** from Eli Lilly, helped people with overweight or obesity lose **up to 20% of their body weight in a Phase 2 trial**, offering a potential alternative to today’s GLP-1 drugs like Wegovy and Ozempic.[1][2][3] Unlike current medications that target the hormone GLP-1, **eloralintide works on a different pathway**: it is a selective **amylin receptor agonist**, mimicking the hormone amylin, which is released from the pancreas when we eat.[1][3] By acting like amylin, **eloralintide appears to curb appetite, slow how quickly the stomach empties, and support metabolic regulation**, all of which can contribute to meaningful weight loss.[1][3] In the Phase 2 study, **263 adults** with overweight or obesity, at least one weight-related health condition, and no type 2 diabetes were assigned to various doses of eloralintide or a placebo injection for **48 weeks**.[1][2] Across all eloralintide dose groups, participants lost an **average of 9–20% of their body weight**, compared with just **0.4%** in the placebo group, a difference researchers described as “clinically impactful.”[1][2][3] Doctors noted that with this level of weight loss, people often see **improvement or even resolution of conditions** like high blood pressure, high cholesterol, osteoarthritis, and sleep apnea, which are commonly tied to excess weight.[1][3] Researchers also reported that those on eloralintide had **better cardiometabolic markers**, including smaller waistlines, lower blood pressure, improved blood sugar control, healthier lipid profiles, and reduced inflammation indicators, all of which may lower long-term heart and metabolic disease risk.[1][2][3] Importantly, **weight loss had not yet plateaued by week 48**, suggesting that people might lose even more weight if treatment continues longer, though that still needs to be confirmed in future research.[1][3] Up to **90% of participants taking eloralintide moved down at least one BMI category**, a sign that the drug could help many people shift out of higher-risk weight ranges when used under medical supervision.[1][3] Like other injectable weight loss medications, **side effects were mostly gastrointestinal**—such as nausea or stomach issues—plus fatigue, and these tended to be **mild to moderate** and more common at higher doses, though longer-term monitoring is still essential.[1][3] Experts say these results put eloralintide’s performance **in a similar range to current GLP-1 medications**, but stress that more time and bigger studies are needed to understand how it compares in real-world use and how safe it is over several years.[1][2][3] Because eloralintide uses a **different hormone pathway than GLP-1 drugs**, obesity specialists are hopeful it could **expand the treatment toolbox**, offering an option for people who do not respond well to, or cannot tolerate, existing medications.[1][3] Researchers and Eli Lilly are now **moving eloralintide into Phase 3 clinical trials**, which will enroll a larger and more diverse population to better define its effectiveness, safety, and its potential role in long-term, personalized obesity care.[1][2][3] Help with your insurance? https://tally.so/r/n012P9